Membership | ACS GCI Pharmaceutical Roundtable
The ACS GCI Pharmaceutical Roundtable welcomes the active participation of companies meeting the following eligibility descriptions:
Any corporation, or subsidiary, division or unit thereof, significantly engaged in the manufacture and marketing of finished dosage form ethical pharmaceutical or biological products under his or its own brand names for the cure, alleviation, mitigation, treatment, prevention or diagnosis of disease, and significantly engaged in pharmaceutical, biopharmaceutical or biological research and development of new molecular entities or new therapies, preventative, or in vivo diagnostics, or new systems of therapy, prevention, or diagnosis and who will continue to conduct such research and development.
Associate Membership Eligibility
Associates shall be corporations, or subsidiaries, divisions or units thereof, not eligible for membership under Members above, who are:
- Significantly engaged in research and development on their own behalf or as a provider of contract research and development services to companies meeting the definition of Member, directly related to the development or production of ethical pharmaceutical or biological products for the cure, alleviation, mitigation, treatment or prevention of disease.
- Significantly engaged in the manufacture of intermediates, active pharmaceutical ingredient, or finished dosage form ethical pharmaceutical or biological products.
Associates shall have all the rights, privileges and duties prescribed by the Business Plan, and such other rights, privileges and duties as the Management Team may from time to time establish by resolution, except the right to vote.
Membership fees are restricted for the purpose of meeting the project needs of the Roundtable. Annual fees range from $10,000 to $25,000 depending on company sales.